A vaccine to prevent cancer in people with Lynch Syndrome
Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome
This project is developing a vaccine to help prevent various cancers in people who have Lynch Syndrome.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11132877 on NIH RePORTER |
What this research studies
For people with Lynch Syndrome, a genetic condition increases their risk of many cancers, especially colorectal cancer. This research builds on findings that their immune system can recognize unique cancer markers. We are working to create a vaccine that targets these markers, called neoantigens, which are specific to Lynch Syndrome-related cancers. The goal is to combine this vaccine with an anti-inflammatory medicine, naproxen, to boost the body's natural defenses against cancer development. This work uses a special animal model to ensure the vaccine is safe and effective before it can be tested in people.
Who could benefit from this research
Good fit: This research is relevant for individuals diagnosed with Lynch Syndrome, particularly those at high risk for various cancers.
Not a fit: Patients without Lynch Syndrome or other hereditary cancer syndromes would likely not benefit directly from this specific vaccine approach.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces the risk of developing multiple cancers for individuals with Lynch Syndrome.
How similar studies have performed: Previous human trials have shown that certain medications can activate the immune system in Lynch Syndrome patients, and a detailed catalog of cancer markers has been identified, suggesting a strong foundation for this vaccine approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Vilar Sanchez, Eduardo — University of Tx Md Anderson Can Ctr
- Study coordinator: Vilar Sanchez, Eduardo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.